Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Search for New Paradigm of Pre-emptive Pathogen Reduction and Pathogen Inactivation to Infuse High Growth into European Blood Pathogen Inactivation - Search for New Paradigm of Pre-emptive Pathogen Reduction and Pathogen Inactivation to Infuse High Growth into European Blood Pathogen Inactivation Market, says Frost & Sullivan
Search for New Paradigm of Pre-emptive Pathogen Reduction and Pathogen Inactivation to Infuse High Growth into European Blood Pathogen Inactivation

 

PRZOOM - /newswire/ - London, United Kingdom, 2010/10/12 - Search for New Paradigm of Pre-emptive Pathogen Reduction and Pathogen Inactivation to Infuse High Growth into European Blood Pathogen Inactivation Market, says Frost & Sullivan.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Although remarkable advances have been made in the prevention of the major transfusion-transmitted diseases, long intervals have transpired between the first recognition of transfusion risk and the implementation of a preventive strategy. For hepatitis B virus, that interval was 30 years; for non-A non-B/hepatitis C virus, 15 years; and for human immunodeficiency virus, West Nile virus, Trypanosoma cruzi and bacteria, 3, 4, 5 and 18 years, respectively. In the existing reactive approach, there is a fundamental and inevitable delay before the government healthcare authorities can react; thus, infections are destined to occur. The continued emergence or re-emergence of transfusion-transmitted infections calls for a new paradigm of pre-emptive pathogen reduction (PR) and pathogen inactivation (PI).

New analysis from Frost & Sullivan (drugdiscovery.frost.com), European Blood Pathogen Inactivation Market, finds that the market generated revenues of about $238.5 in 2009 and estimates this to reach $521.5 million by 2013, as this is an early growth stage market with very good potential for growth. The following segments are covered in the research: platelets, plasma and red blood cells.

Platelets are highly susceptible to bacterial contamination and therefore cannot be stored for more than 5 days. If the bacterial count is too low to detect, it has to be repeatedly cultured and sub-cultured to verify the number of colony-forming units, by which time, even platelet units that might have initially been usable, become contaminated and expire.

"Therefore, in the case of platelets, PI makes good sense as it helps to extend the storage days from 5 to 7 days," notes Frost & Sullivan Senior Research Analyst Rasika Ramachandran. "Having two extra days also helps blood centres to manage their inventory better and could mean the difference between having and not having platelet units for transfusion in an emergency situation."

The European blood pathogen inactivation market is currently growing at a double-digit rate, which is significant even if it comes from a low base. This growth rate is projected to increase as more new products gain regulatory approval and enter the market.

Currently, there is no single PI method that is effective against all pathogens. This is a major drawback for the entire blood pathogen inactivation market, which leads to low uptake of PI techniques. In addition, it is impractical due to the labour intensiveness and cost issues, as currently, multiple inactivation techniques need to be applied to a unit of blood component.

"This is anticipated to be a key challenge in this market until one of two things happens," states Ramachandran. "One, the significant cost reduction of existing methods or two, the discovery of a single all-encompassing pathogen inactivation technique, neither of which seem to be on the visible horizon."

There are indications from industry participants that they are focusing on the issue of performing economic cost-benefit analyses. This will raise confidence among healthcare authorities in the adoption of blood PI techniques.

"Although the industry is currently focusing its resources towards clinical validation and gaining marketing approval in various regions in Europe, it is imperative that some resources be allocated towards performing cost-benefit analyses," concludes Ramachandran.

If you are interested in more information on this study, please send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

European Blood Pathogen Inactivation Market is part of the Drug Discovery Technologies Growth Partnership Services programme, which also includes research on the following markets: European Lab-on-chip and Microfluidics Market and, European Biomarker Analysis Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

European Blood Pathogen Inactivation Market / M4A6

Follow Frost & Sullivan on Twitter and Facebook:
twitter.com/frost_sullivan
facebook.com/FrostandSullivan

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Search for New Paradigm of Pre-emptive Pathogen Reduction and Pathogen Inactivation to Infuse High Growth into European Blood Pathogen Inactivation

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Katja Feick 
+49 (0) 69 7703343 katja.feick[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  1Click Games







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today